These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 33812443)
21. Advances for the treatment of primary central nervous system lymphoma (review). Yamanaka R; Tanaka R Oncol Rep; 2004 Sep; 12(3):563-8. PubMed ID: 15289838 [TBL] [Abstract][Full Text] [Related]
22. [Outcomes of primary central nervous system lymphoma patients treated with high-dose methotrexate and rituximab]. Shiota Y; Dobashi N; Ito Y; Hosoba R; Yamauchi H; Ishii H; Nakano A; Fukushima R; Ohba R; Yahagi Y; Usui N; Yano S Rinsho Ketsueki; 2019; 60(2):87-92. PubMed ID: 30842385 [TBL] [Abstract][Full Text] [Related]
23. Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment. Zhang Y; Zhou DB Chin Med J (Engl); 2020 Jun; 133(12):1462-1469. PubMed ID: 32452898 [TBL] [Abstract][Full Text] [Related]
24. Primary Central Nervous System Lymphoma. Sinicrope K; Batchelor T Neurol Clin; 2018 Aug; 36(3):517-532. PubMed ID: 30072069 [TBL] [Abstract][Full Text] [Related]
25. Central Nervous System Lymphoma: Novel Therapies. Fortin Ensign SP; Gathers D; Wiedmeier JE; Mrugala MM Curr Treat Options Oncol; 2022 Jan; 23(1):117-136. PubMed ID: 35182298 [TBL] [Abstract][Full Text] [Related]
26. Primary Central Nervous System Lymphoma: Clinical Characteristics, Treatment Options and Therapeutic Outcome in 36 Patients. A Single Center Experience. Zektser M; Rabinovich A; Grinbaum U; Porges T; Gozlan A; Gourevitch A; Al-Athamen K; Barrett O; Peles I; Kaisman-Elbaz T; Levi E Isr Med Assoc J; 2022 Oct; 24(10):654-660. PubMed ID: 36309861 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic management of refractory or relapsed primary central nervous system lymphomas. Reni M; Ferreri AJ Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691 [TBL] [Abstract][Full Text] [Related]
28. The outcome of ibrutinib-based regimens in relapsed/refractory central nervous system lymphoma and the potential impact of genomic variants. Wang S; Zhu Y; Qian X; Ding T; Yuan Y; Li Y; Wu H; Chen T Adv Clin Exp Med; 2023 Aug; 32(8):855-863. PubMed ID: 36881367 [TBL] [Abstract][Full Text] [Related]
29. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Grommes C; Tang SS; Wolfe J; Kaley TJ; Daras M; Pentsova EI; Piotrowski AF; Stone J; Lin A; Nolan CP; Manne M; Codega P; Campos C; Viale A; Thomas AA; Berger MF; Hatzoglou V; Reiner AS; Panageas KS; DeAngelis LM; Mellinghoff IK Blood; 2019 Jan; 133(5):436-445. PubMed ID: 30567753 [TBL] [Abstract][Full Text] [Related]
30. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443 [TBL] [Abstract][Full Text] [Related]
31. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. Korfel A; Thiel E Leuk Lymphoma; 1998 Aug; 30(5-6):609-17. PubMed ID: 9711923 [TBL] [Abstract][Full Text] [Related]
32. New approaches in primary central nervous system lymphoma. Fraser E; Gruenberg K; Rubenstein JL Chin Clin Oncol; 2015 Mar; 4(1):11. PubMed ID: 25841718 [TBL] [Abstract][Full Text] [Related]
33. Review of rituximab in primary CNS lymphoma. Singh PK; Pan E J Neurol Sci; 2020 Mar; 410():116649. PubMed ID: 31901591 [TBL] [Abstract][Full Text] [Related]
34. Introduction of novel agents in the treatment of primary CNS lymphoma. Grommes C; Nayak L; Tun HW; Batchelor TT Neuro Oncol; 2019 Feb; 21(3):306-313. PubMed ID: 30423172 [TBL] [Abstract][Full Text] [Related]
35. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; SorarĂ¹ M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567 [TBL] [Abstract][Full Text] [Related]
37. [Medical management of primary central nervous system lymphoma refractory or resistant to standard of care treatment]. Yamanaka R Brain Nerve; 2009 Oct; 61(10):1155-64. PubMed ID: 19882942 [TBL] [Abstract][Full Text] [Related]
38. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly. Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800 [TBL] [Abstract][Full Text] [Related]
39. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience. Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898 [TBL] [Abstract][Full Text] [Related]
40. Diagnosis and management of primary central nervous system lymphoma. Han CH; Batchelor TT Cancer; 2017 Nov; 123(22):4314-4324. PubMed ID: 28950405 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]